About: Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series
Creator	Schmiedel, Stefan Addo, Marylyn Dahlke, Christine Fathi, Anahita Seeberger, Peter Kobbe, Robin Koch, Till Ly, My Heidepriem, Jasmin Loeffler, Felix Santer, René
Source	MedRxiv
abstract	SARS-CoV-2 is the causative agent of COVID-19 and is a severe threat to global health. Patients infected with SARS-CoV-2 show a wide range of symptoms and disease severity, while limited data is available on its immunogenicity. Here, the kinetics of the development of SARS-CoV-2-specific antibody responses in relation to clinical features and dynamics of specific B-cell populations are reported. Immunophenotyping of B cells was performed by flow cytometry with longitudinally collected PBMCs. In parallel, serum samples were analyzed for the presence of SARS-CoV-2-specific IgA, IgG, and IgM antibodies using whole proteome peptide microarrays. Soon after disease onset in a mild case, we observed an increased frequency of plasmablasts concomitantly with a strong SARS-CoV-2-specific IgA response. In contrast, a case with more severe progression showed a delayed, but eventually very strong and broad SARS-CoV-2-specific IgA response. This case study shows that determining SARS-CoV-2-specific antibody epitopes can be valuable to monitor the specificity and magnitude of the early B-cell response, which could guide the development of vaccine candidates. Follow-up studies are required to evaluate whether the kinetics and strength of the SARS-CoV-2-specific IgA response could be potential prognostic markers of viral control.
has issue date	2020-04-17(xsd:dateTime)
bibo:doi	10.1101/2020.04.14.20059733
has license	medrxiv
sha1sum (hex)	3d87e960199b59aae86aeee5702121fd382b35ca
schema:url	https://doi.org/10.1101/2020.04.14.20059733
resource representing a document's title	Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series
resource representing a document's body	covid:3d87e960199b59aae86aeee5702121fd382b35ca#body_text
is schema:about of	named entity 'severe' named entity 'case series' named entity 'THREAT' named entity 'causative agent' named entity 'COVID-19' named entity 'vaccines' named entity 'spike protein' named entity 'IgA' named entity 'peptides' named entity 'peer-reviewed' named entity 'Serum samples' named entity 'immune response' named entity 'mg/dl' named entity 'IgG' named entity 'proteome' named entity 'infection' named entity 'IgG' named entity 'peptides' named entity 'IgA' named entity 'SARS-CoV-2' named entity 'IgM' named entity 'medRxiv' named entity 'IgA' named entity 'monoclonal antibodies' named entity 'fusion peptide' named entity 'IgM' named entity 'Ficoll' named entity 'viral load' named entity 'microarray' named entity 'headache' named entity 'tested positive' named entity 'productive cough' named entity 'epitopes' named entity 'viral proteome' named entity 'Medical Association' named entity 'IgA' named entity 'viruses' named entity 'genetic similarity' named entity 'nucleocapsid' named entity 'vaccines' named entity 'antibodies' named entity 'infection' named entity 'microarrays' named entity 'protein' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'peptide' named entity 'medRxiv' named entity 'IgG' named entity 'PBMCs' named entity 'IgG' named entity 'plasmablasts' named entity 'viruses' named entity 'peptides' named entity 'spike protein' named entity '1:200' named entity 'immunogenicity' named entity 'medRxiv' named entity 'peptide' named entity 'myalgia' named entity 'cough' named entity 'SARS-CoV' named entity 'medRxiv' named entity 'receptor binding domain' named entity 'nucleocapsid' named entity 'viral shedding' named entity 'COVID' named entity 'coronavirus' named entity 'peer-reviewed' named entity 'University Medical Center Hamburg-Eppendorf' named entity 'fluorescently labeled' named entity 'immunogenicity' named entity 'IgA' named entity 'fever' named entity 'IgA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software